Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer - PubMed
2 hours ago
- #therapy resistance
- #structural variants
- #prostate cancer
- Complex structural variants (cSVs), especially extra-chromosomal DNA (ecDNA), are common in metastatic castration-resistant prostate cancer (mCRPC) and amplify driver genes like AR and MYC.
- cSVs contribute to therapy resistance and evolve in response to AR pathway inhibitor therapy, detectable in tumor tissue and circulating tumor DNA.
- Phylogenetic analysis indicates that cSVs, including AR amplification, arise early in metastatic spread and drive intra-patient heterogeneity in late-stage mCRPC.